Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with…